Fed Circuit won’t revisit Sanofi’s PTAB appeal despite Arthrex

30-01-2020

Rory O'Neill

Fed Circuit won’t revisit Sanofi’s PTAB appeal despite Arthrex

Photobyphm / Shutterstock.com

The US Court of Appeals for the Federal Circuit has thrown out Sanofi’s request to apply the recent Arthrex ruling on the constitutionality of the Patent Trial and Appeal Board (PTAB) to more cases.


US Court of Appeals for the Federal Circuit, Arthrex, Sanofi, Mylan Pharmaceuticals, Patent Trial and Appeal Board, insulin

LSIPR